Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT05100641 is registered in ClinicalTrials.gov with Aivita Biomedical, Inc. as lead sponsor.

NCT NCT05100641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05100641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Aivita Biomedical, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2024
Completion date
March 31, 2029
Enrollment
672 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary glioblastoma